AT506820B1 - Vakzine gegen alzheimer-krankheit - Google Patents

Vakzine gegen alzheimer-krankheit Download PDF

Info

Publication number
AT506820B1
AT506820B1 AT0095208A AT9522008A AT506820B1 AT 506820 B1 AT506820 B1 AT 506820B1 AT 0095208 A AT0095208 A AT 0095208A AT 9522008 A AT9522008 A AT 9522008A AT 506820 B1 AT506820 B1 AT 506820B1
Authority
AT
Austria
Prior art keywords
peptide
mimotope
amino acid
compound
prt
Prior art date
Application number
AT0095208A
Other languages
German (de)
English (en)
Other versions
AT506820A1 (de
Original Assignee
Affiris Forschungs Und Entwicklungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ATA416/2010A priority Critical patent/AT509611B1/de
Application filed by Affiris Forschungs Und Entwicklungs Gmbh filed Critical Affiris Forschungs Und Entwicklungs Gmbh
Priority to AT0095208A priority patent/AT506820B1/de
Priority to BRPI0915136A priority patent/BRPI0915136A2/pt
Priority to KR1020117000819A priority patent/KR20110036809A/ko
Priority to AU2009257168A priority patent/AU2009257168B2/en
Priority to KR1020117000810A priority patent/KR20110036039A/ko
Priority to US12/997,673 priority patent/US8409581B2/en
Priority to RU2011100127/15A priority patent/RU2011100127A/ru
Priority to RU2011100125/15A priority patent/RU2491953C2/ru
Priority to PCT/AT2009/000237 priority patent/WO2009149487A2/en
Priority to CA2723967A priority patent/CA2723967A1/en
Priority to BRPI0915134A priority patent/BRPI0915134A2/pt
Priority to JP2011512782A priority patent/JP2011522842A/ja
Priority to MX2010013647A priority patent/MX2010013647A/es
Priority to JP2011512780A priority patent/JP2011522840A/ja
Priority to PCT/AT2009/000235 priority patent/WO2009149485A2/en
Priority to CN200980131376.3A priority patent/CN102123728B/zh
Priority to EP20090761154 priority patent/EP2310032A2/en
Priority to CA2723995A priority patent/CA2723995A1/en
Priority to EP09761152A priority patent/EP2310033B1/en
Priority to AU2009257170A priority patent/AU2009257170B2/en
Priority to CN2009801313674A priority patent/CN102123726A/zh
Priority to ES09761152T priority patent/ES2392789T3/es
Priority to MX2010013657A priority patent/MX2010013657A/es
Priority to US12/997,702 priority patent/US20110092436A1/en
Publication of AT506820A1 publication Critical patent/AT506820A1/de
Priority to IL209896A priority patent/IL209896A0/en
Priority to IL209894A priority patent/IL209894A/en
Application granted granted Critical
Publication of AT506820B1 publication Critical patent/AT506820B1/de
Priority to US13/770,594 priority patent/US20130287807A1/en
Priority to JP2014073229A priority patent/JP5984867B2/ja
Priority to JP2014263345A priority patent/JP5989074B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT0095208A 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit AT506820B1 (de)

Priority Applications (30)

Application Number Priority Date Filing Date Title
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit
ATA416/2010A AT509611B1 (de) 2008-06-12 2008-06-12 Vakzin
CN200980131376.3A CN102123728B (zh) 2008-06-12 2009-06-12 用于治疗淀粉样变的化合物
AU2009257168A AU2009257168B2 (en) 2008-06-12 2009-06-12 Compounds for treating Amyloidoses
KR1020117000810A KR20110036039A (ko) 2008-06-12 2009-06-12 아밀로이드증을 치료하기 위한 화합물
US12/997,673 US8409581B2 (en) 2008-06-12 2009-06-12 Compounds for treating amyloidoses
RU2011100127/15A RU2011100127A (ru) 2008-06-12 2009-06-12 Соединение, содержащее пептид, для лечения симптомов болезни паркинсона
RU2011100125/15A RU2491953C2 (ru) 2008-06-12 2009-06-12 Соединения для лечения амилоидозов
PCT/AT2009/000237 WO2009149487A2 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
CA2723967A CA2723967A1 (en) 2008-06-12 2009-06-12 Compounds for treating amyloidoses
BRPI0915134A BRPI0915134A2 (pt) 2008-06-12 2009-06-12 composto, e, uso de um composto
JP2011512782A JP2011522842A (ja) 2008-06-12 2009-06-12 パーキンソン病に関連する症状の治療のための化合物
MX2010013647A MX2010013647A (es) 2008-06-12 2009-06-12 Compuestos para tratar sintomas asociados con la enfermedad de parkinson.
JP2011512780A JP2011522840A (ja) 2008-06-12 2009-06-12 アミロイドーシス治療のための化合物
BRPI0915136A BRPI0915136A2 (pt) 2008-06-12 2009-06-12 uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
EP20090761154 EP2310032A2 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
AU2009257170A AU2009257170B2 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with Parkinson's disease
KR1020117000819A KR20110036809A (ko) 2008-06-12 2009-06-12 파킨슨병과 관련된 증상을 치료하기 위한 화합물
EP09761152A EP2310033B1 (en) 2008-06-12 2009-06-12 Peptide compounds for treating amyloidoses
CA2723995A CA2723995A1 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
CN2009801313674A CN102123726A (zh) 2008-06-12 2009-06-12 用于治疗与帕金森氏病有关的症状的化合物
ES09761152T ES2392789T3 (es) 2008-06-12 2009-06-12 Compuestos peptídicos para tratar las amiloidosis.
MX2010013657A MX2010013657A (es) 2008-06-12 2009-06-12 Compuestos para tratar la amiloidosis.
US12/997,702 US20110092436A1 (en) 2008-06-12 2009-06-12 Compounds for treating symptoms associated with parkinson's disease
PCT/AT2009/000235 WO2009149485A2 (en) 2008-06-12 2009-06-12 Compounds for treating amyloidoses
IL209896A IL209896A0 (en) 2008-06-12 2010-12-09 Compounds for treating symptoms associated with parkinson's disease
IL209894A IL209894A (en) 2008-06-12 2010-12-09 Compounds for the prevention and / or treatment of β-amyloidosis including Alzheimer's disease
US13/770,594 US20130287807A1 (en) 2008-06-12 2013-02-19 Compounds for treating symptoms associated with parkinson's disease
JP2014073229A JP5984867B2 (ja) 2008-06-12 2014-03-31 アミロイドーシス治療のための化合物
JP2014263345A JP5989074B2 (ja) 2008-06-12 2014-12-25 アミロイドーシス治療のための化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit

Publications (2)

Publication Number Publication Date
AT506820A1 AT506820A1 (de) 2009-12-15
AT506820B1 true AT506820B1 (de) 2011-07-15

Family

ID=41401983

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit
ATA416/2010A AT509611B1 (de) 2008-06-12 2008-06-12 Vakzin

Family Applications After (1)

Application Number Title Priority Date Filing Date
ATA416/2010A AT509611B1 (de) 2008-06-12 2008-06-12 Vakzin

Country Status (14)

Country Link
US (1) US8409581B2 (https=)
EP (1) EP2310033B1 (https=)
JP (3) JP2011522840A (https=)
KR (1) KR20110036039A (https=)
CN (1) CN102123728B (https=)
AT (2) AT506820B1 (https=)
AU (1) AU2009257168B2 (https=)
BR (1) BRPI0915136A2 (https=)
CA (1) CA2723967A1 (https=)
ES (1) ES2392789T3 (https=)
IL (1) IL209894A (https=)
MX (1) MX2010013657A (https=)
RU (1) RU2491953C2 (https=)
WO (1) WO2009149485A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
BR112013023211B1 (pt) 2011-03-16 2022-11-08 Vivoryon Therapeutics N.V. Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
SI2579042T1 (sl) 2011-10-04 2014-09-30 Affiris Ag Postopek za detektiranje Ass-specifičnih protiteles v biološkem vzorcu
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
EP3137097B1 (en) * 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)
PL3137094T3 (pl) 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
CN115925987A (zh) * 2022-02-28 2023-04-07 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
WO1999051254A1 (en) * 1998-04-06 1999-10-14 Advanced Immunit, Inc. Short peptides for treatment of neurological degenerative diseases
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
DE69942274D1 (de) * 1998-05-21 2010-06-02 Univ Tennessee Res Foundation Methoden zur amyloidentfernung mit anti-amyloid-antikörper
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
CN100571701C (zh) * 2002-12-24 2009-12-23 贝卢斯健康(国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
CA2790433A1 (en) * 2004-10-25 2006-05-26 Northwestern University Anti-addl antibodies and uses thereof
US20100152418A1 (en) * 2005-06-17 2010-06-17 Epfl Ecole Polytechnique Federale De Lausanne Switch-Peptides as Tool for the Study of Fibrillogenesis
SG10201404801YA (en) * 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
EP1992639A4 (en) * 2006-02-22 2009-08-26 Hayashibara Biochem Lab PEPTIDE VACCINE FOR INDUCING THE PRODUCTION OF AN ANTIAMYLOID PEPTIDANT BODY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes

Also Published As

Publication number Publication date
KR20110036039A (ko) 2011-04-06
AU2009257168A1 (en) 2009-12-17
JP2015110588A (ja) 2015-06-18
BRPI0915136A2 (pt) 2019-09-24
EP2310033A2 (en) 2011-04-20
JP5984867B2 (ja) 2016-09-06
AU2009257168B2 (en) 2015-01-22
CN102123728A (zh) 2011-07-13
IL209894A0 (en) 2011-02-28
AT509611A1 (de) 2011-10-15
CA2723967A1 (en) 2009-12-17
JP2014139227A (ja) 2014-07-31
IL209894A (en) 2015-08-31
EP2310033B1 (en) 2012-09-05
RU2011100125A (ru) 2012-07-20
RU2491953C2 (ru) 2013-09-10
JP5989074B2 (ja) 2016-09-07
JP2011522840A (ja) 2011-08-04
AT509611B1 (de) 2012-04-15
US20110171243A1 (en) 2011-07-14
AT506820A1 (de) 2009-12-15
ES2392789T3 (es) 2012-12-13
US8409581B2 (en) 2013-04-02
WO2009149485A3 (en) 2010-06-10
MX2010013657A (es) 2011-04-11
WO2009149485A2 (en) 2009-12-17
CN102123728B (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
AT506820B1 (de) Vakzine gegen alzheimer-krankheit
AT509106B1 (de) Vakzin zur behandlung von alzheimer krankheit
AT506535B1 (de) Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508638B1 (de) Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
US20130287807A1 (en) Compounds for treating symptoms associated with parkinson's disease
HK1152470B (en) Peptides for treating beta-amyloidoses

Legal Events

Date Code Title Description
MM01 Lapse because of not paying annual fees

Effective date: 20160612